Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

NCT01197066 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Certolizumab Pegol

Sponsor

Korea Otsuka Pharmaceutical Co., Ltd.